Jamjoom Pharmaceuticals Factory Company (TADAWUL: 4015)

Market Cap	11.44B
Revenue (ttm)	1.27B
Net Income (ttm)	349.40M
Shares Out	70.00M
EPS (ttm)	4.99
PE Ratio	32.74
Forward PE	27.93
Dividend	3.20 (1.96%)
Ex-Dividend Date	Aug 18, 2024

Volume	52,345
Average Volume	86,602
Open	165.00
Previous Close	165.00
Day's Range	162.60 - 165.00
52-Week Range	124.80 - 202.40
Beta	n/a
RSI	54.71
Earnings Date	Mar 26, 2025

About Jamjoom Pharmaceuticals Factory Company

Jamjoom Pharmaceuticals Factory Company manufactures and markets pharmaceutical products in the Kingdom of Saudi Arabia and internationally. The company offers products human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer, and acidity, as well as various skin infections, cancer diseases, eye drops and ointments, and cosmeceuticals. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Country: Saudi Arabia
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2023, Jamjoom Pharmaceuticals Factory Company's revenue was 1.10 billion, an increase of 20.09% compared to the previous year's 916.67 million. Earnings were 292.40 million, an increase of 70.68%.